Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as S303 Red Blood Cells (RBCs), S-303 Red Blood Cells (RBCs) - Test, S-303 Red Blood Cells- Test
S303 Red Blood Cells · 1 trial · 1 indication
The mean hemoglobin content per red blood cell (RBC) component compared between the treatment groups
The frequency of adverse events (related and unrelated to study RBC components) will be compared between the treatment groups.
| Arm | Type | Description |
|---|---|---|
| S-303 Treated Red Blood Cells | EXPERIMENTAL | Patients receive S-303 treated red blood cells (RBCs). |
| Conventional, untreated Red Blood Cells | ACTIVE_COMPARATOR | Patients receive conventional, untreated red blood cells (RBCs). |
| Name | Type | Description |
|---|---|---|
| S-303 Red Blood Cells (RBCs) - Test | BIOLOGICAL | - |
| Conventional, untreated red blood cells (RBCs) - Control | BIOLOGICAL | - |
Inclusion Criteria: 1. Age ≥18 years, of either gender. 2. Must be willing to use an acceptable form of contraceptive while on study (as approved by the Investigator or designee) 3. Must be readily available by telephone 4. Must provide an informed consent for study participation and have signed an...
S303 Red Blood Cells is an investigational blood product developed by Cerus Corporation for transfusion support in patients with acute anemia. It is being studied as an alternative to conventional red blood cell transfusions. The program reached Phase 3 clinical development in hematology.
S303 Red Blood Cells is being developed for transfusion support in patients with acute anemia. The focus is on patients who require red blood cell transfusion, with the goal of providing a pathogen-reduced red blood cell component for that support.
Cerus Corporation, which trades on the Nasdaq under the ticker CERS, is developing S303 Red Blood Cells. The company is the sponsor of the clinical program evaluating the product in patients with acute anemia.
S303 Red Blood Cells has completed a Phase 3 clinical trial. It is an investigational product and is not described as approved; the Phase 3 study has finished and no trials are currently listed as active.
S303 Red Blood Cells was studied in NCT01716923, a Phase 3 trial titled Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia. The trial enrolled 81 patients in Germany, was randomized, double blind, and active controlled, and is completed.
Yes. S303 Red Blood Cells is also referred to as S303 Red Blood Cells (RBCs), S-303 Red Blood Cells (RBCs) - Test, and S-303 Red Blood Cells - Test. These names refer to the same Cerus Corporation red blood cell product in development for acute anemia transfusion support.